Tin tức & Cập nhật

Tapinarof cream effective regardless of AD severity, age in two trials

15 Mar 2024 bởi

Once-daily application of tapinarof cream 1% significantly improves the Eczema Area Severity Index (EASI) score in patients with atopic dermatitis (AD), regardless of their disease severity or age, according to the pivotal phase III ADORING 1 and 2 trials presented at AAAAI 2024.

Tapinarof cream effective regardless of AD severity, age in two trials

15 Mar 2024

TRuE-AD3: Ruxolitinib cream effective in children with AD

11 Mar 2024 bởi

Ruxolitinib cream, a topically administered selective Janus kinase 1/2 inhibitor, appears to be effective for mild-to-moderate atopic dermatitis (AD) in children aged 2–11 years, according to the TRuE-AD3 trial presented at AAAAI 2024.

TRuE-AD3: Ruxolitinib cream effective in children with AD

11 Mar 2024

Sebetralstat fares well as oral therapy for HAE

08 Mar 2024 bởi

In the phase III KONFIDENT trial, oral sebetralstat provides rapid symptom relief, cuts treatment burden, and facilitates early treatment in individuals with hereditary angioedema (HAE) attacks.

Sebetralstat fares well as oral therapy for HAE

08 Mar 2024

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

05 Mar 2024 bởi

Omalizumab scores in the NIH*-sponsored phase III OUtMATCH** trial, increasing the threshold for an allergic reaction to peanut and other common food allergens in children and adults with multiple food allergies.

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

05 Mar 2024

Investigational drug scores big in mild-to-moderate AD, plaque psoriasis

29 Feb 2024

The topical phosphodiesterase 4 inhibitor PF-07038124 is safe and helps lower disease activity in patients with mild-to-moderate atopic dermatitis (AD) and plaque psoriasis, according to the results of a phase IIa study.

Investigational drug scores big in mild-to-moderate AD, plaque psoriasis

29 Feb 2024

Ertapenem infusion beneficial in hidradenitis suppurativa

24 Feb 2024

Treatment with intravenous ertapenem yields improvements in the clinical and inflammatory markers of hidradenitis suppurativa (HS), according to a retrospective study.

Ertapenem infusion beneficial in hidradenitis suppurativa

24 Feb 2024

Children of mothers with AD prone to develop AD, other allergic illness

22 Feb 2024

Children whose mothers have atopic dermatitis (AD) are likely to develop the same disease, while some develop other allergic illness (OAI) first, reports a study. This suggests that not everyone will follow the same sequential pathway.

Children of mothers with AD prone to develop AD, other allergic illness

22 Feb 2024

5-year survival more likely in mBCC patients with nodal vs distant metastasis

21 Feb 2024

Among patients with metastatic basal cell carcinoma (mBCC), those with nodal disease appear to have a higher chance of remission, while individuals with distant metastasis tend to have persistent disease and subsequently die from it, a recent study reveals. However, the survival rates at 5 years surpass 50 percent even for those with stage IV disease.